Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

How to verify SLU-PP-332 purity and batch documentation

A laboratory-focused guide to verifying SLU-PP-332 purity and batch documentation, covering analytical characterization, in vitro metabolism, and the limits of the current evidence base.

peptides-pro Editorial

SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), also referred to as a pan-ERR agonist and an exercise mimetic in the research literature. The evidence block for this page does not provide a sequence, molecular formula, or molecular weight for the compound, so those identifiers cannot be stated here. What the evidence does establish is that SLU-PP-332 has been characterized by liquid chromatography–high resolution (tandem) mass spectrometry (LC-HRMS/MS), and that its in vitro metabolic transformation products have been prepared using human liver S9 fractions [1].

The work on this scaffold centres on the estrogen-related receptor (ERR) family of orphan nuclear receptors, which regulate genes involved in mitochondrial metabolism and exercise-responsive transcription [2].

Research Studies

SLU-PP-332 and analytical characterization by LC-HRMS/MS

SLU-PP-332 and a related pan-ERR agonist, SLU-PP-915, were characterized using liquid chromatography–high resolution (tandem) mass spectrometry (LC-HRMS/MS) [1]. This is the analytical method reported in the evidence for identifying the compound and distinguishing it from related structures. For a laboratory verifying a batch, LC-HRMS/MS is the technique the cited work used to establish the identity of the parent compound and its transformation products.

SLU-PP-332 and in vitro metabolism in human liver S9 fractions

In vitro metabolic transformation products of SLU-PP-332 were prepared using human liver S9 fractions [1]. The same study prepared transformation products for SLU-PP-915 under the same conditions. This matters for batch documentation because it establishes a reference set of metabolites against which an unknown sample can be compared. The evidence does not report a metabolic stability figure, a half-life, or a percentage conversion for SLU-PP-332, so none is stated here.

SLU-PP-332 and structure-activity relationship analysis

A comprehensive structure-activity relationship (SAR) analysis of the SLU-PP-332 scaffold has been reported, integrating chemical synthesis, cell-based functional assays, and downstream gene-expression profiling [2]. The same work notes that the structural features governing potency, efficacy, selectivity, and drug-like properties of SLU-PP-332 had not previously been systematically elucidated [2]. For a purity assessment, this is relevant because structural analogues of the parent scaffold are the most likely co-eluting impurities, and the SAR work defines which regions of the molecule tolerate substitution.

SLU-PP-332 and ERR activation in human myoblasts from inactive women

A pilot study evaluated ERR targeting in myoblasts isolated from the skeletal muscle of inactive women [3]. Twenty women undergoing hip arthroplasty for coxarthrosis were enrolled and divided into an active group (n = 10) and an inactive group (n = 10) based on self-reported physical activity [3]. The study assessed metabolic and expression changes associated with ERR activation in these cells [3]. This is a human-cell, ex vivo model; it is not a clinical trial of SLU-PP-332 in humans, and the evidence does not report a dose, a treatment duration, or an outcome measure for the compound in that population.

SLU-PP-332 and exercise-mimetic status under anti-doping rules

Exercise mimetics and metabolic modulators are prohibited in sports by the World Anti-Doping Agency (WADA) [4]. SLU-PP-332 is described in that context as a small, synthetic ERRα/β/γ agonist [4]. The analytical characterization and in vitro metabolism work cited above was undertaken with sports drug testing programmes in mind, given that ERR agonists such as SLU-PP-332 and SLU-PP-915 can trigger physiological processes similar to those initiated by physical activity [1]. For a laboratory, this is a documentation consideration: the compound sits in a class for which detection methods and metabolite reference standards have been actively developed.

SLU-PP-332 and ERR pharmacology as an exercise-mimetic strategy

A systematic review has examined the physiological, molecular, and clinical evidence on pharmacological activation of ERRα/β/γ as a strategy to mimic exercise-induced effects, in the context of physical inactivity contributing to chronic disease [5]. That review is a secondary source and is cited here as background for why the ERR axis is studied; it is not a primary purity or batch-characterization study.

SLU-PP-332 and the ERR family in skeletal muscle adaptation

ERRα, ERRβ, and ERRγ are orphan nuclear receptors that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and the Krebs cycle, and they are described as essential for skeletal muscle adaptation to aerobic exercise [6]. That same source reports on SLU-PP-915, an orally active ERR agonist, and its effects on aerobic exercise capacity [6]. The evidence block does not report an equivalent aerobic-capacity finding for SLU-PP-332 itself, so none is stated here.

SLU-PP-332 and metabolic syndrome models

SLU-PP-332 has been described in the context of pharmacological exercise mimetics for diseases including obesity and metabolic syndrome [7]. The evidence block does not specify the species or model in which those metabolic findings were obtained, and it does not report effect sizes, so no such values are given here. This item is cited as background on the compound's research history, not as a purity or documentation data point.

SLU-PP-332 and what batch documentation can and cannot establish

Batch documentation for a research compound typically rests on three things: an identity method, a purity method, and a stability or metabolite reference set. For SLU-PP-332, the evidence supports the first and third directly — LC-HRMS/MS characterization and human liver S9-derived transformation products [1] — and supports the second indirectly through the SAR work that maps which structural features govern potency and selectivity [2]. The evidence block does not provide a purity specification, a certificate-of-analysis template, a storage condition, or a retest interval for SLU-PP-332, and none is invented here.

Documentation elementSupported by the evidence for SLU-PP-332Not supported by the evidence
Identity methodLC-HRMS/MS characterization [1]—
Metabolite reference setHuman liver S9 in vitro transformation products [1]—
Structural analogue mapSAR analysis of the SLU-PP-332 scaffold [2]—
Purity specification—No numeric purity value given
Storage and retest interval—No conditions given
Human dosing or clinical outcome—No human trial data for SLU-PP-332

SLU-PP-332 and the limits of the current evidence base

The evidence block for this page contains no human clinical trial of SLU-PP-332. The human-derived material cited is ex vivo: myoblasts isolated from skeletal muscle of inactive women [3]. The remaining primary findings are in vitro (LC-HRMS/MS characterization and human liver S9 metabolism [1]; cell-based functional assays and gene-expression profiling [2]). Where the evidence describes exercise-mimetic or metabolic effects, it does so in the context of review or model-based work whose species and effect sizes are not specified in the block [5][6][7]. A purity or batch-documentation claim for SLU-PP-332 should therefore be built on the analytical evidence, not on any implied physiological outcome.

If you are reading this for personal health reasons

SLU-PP-332 is sold by us for laboratory research use only, and we do not provide dosing, administration, or medical guidance of any kind. Nothing on this page is a recommendation to use this compound in a person. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp